We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Dr. Moein Moghimi -Professor of Pharmaceutics and Nanomedicine- School of Pharmacy, Newcastle University, Division of Stratified Medicine, Biomarkers and Therapeutics, Institute of Cellular Medicine, Newcastle
"Of pigs and men: the illusive story of infusion-reactions to nanoparticulate medicines"
Adverse infusion reactions to regulatory approved nanopharmaceuticals in human subjects are idiosyncratic, but outwardly reproducible in pigs. Equivocal investigations also indict a role for the complement system in adverse reactions to nanopharmaceuticals, where the extent of nanomedicine-mediated complement activation in human serum is curiously correlated to cardiopulmonary responses in pigs. Contrary to these beliefs, a large body of evidence from this and other laboratories suggest that the porcine reactions are related to robust nanoparticle clearance by pulmonary intravascular macrophages (PIMs) irrespective of complement activation, and rapid release of arachidonate metabolites from these cells. Similar to pigs, other animals that have resident PIMs in their lungs also respond to intravenously injected particles, where rapid particle clearance by PIMs correlate with peak periods of cardiopulmonary distress. Normal human lungs, however, do not have PIMs, but “induced” PIMs have been identified in pulmonary circulation dependent on pathological conditions. Apparently, nanomedicine-mediated infusion reactions in humans are related to a moment of macrophage intoxication by induced PIMs and/or other macrophages outside the pulmonary circulation, but avoidable with appropriate dosing or through simple nanoengineering strategies. Notwithstanding, global nanomedicine safety assessment in the porcine model (and other ruminants and species with PIMs) is inappropriate and misleading, and these models should not be advertently promoted and their applications exaggerated
Host: CIBBIM-Nanomedicina. Direccionament i Alliberament Farmacològic simo.schwartz@vhir.org
cartell_de_la_conferencia.pdf
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.